Statin use and MRI subchondral bone marrow lesion worsening in generalized osteoarthritis: longitudinal analysis from Osteoarthritis Initiative data.
Statin use and MRI subchondral bone marrow lesion worsening in generalized osteoarthritis: longitudinal analysis from Osteoarthritis Initiative data.
复制标题
DOI：
10.1007/s00330-021-08471-y
复制
发表时间：
2022-06
影响因子：
5.9
通讯作者：
中科院分区：
文献类型：
--
作者：
确定他汀类药物治疗与Heberden淋巴结（HN）患者膝关节MRI检测到的软骨下骨髓病变（BML）纵向恶化之间的相关性，Heberden淋巴结（HN）是全身性骨关节炎（OA）表型的标志。所有参与者都提供了知情同意书，IRB批准了符合HIPAA的方案。我们使用基线和24个月时的半定量MRI骨关节炎膝关节评分，评估了骨关节炎倡议（OAI）参与者基线临床检查（HN+）时的HN患者BML体积和受累亚区数量的恶化。根据基线BML受累将受试者分类为“无/极轻微”（受累膝关节亚区≤2/14，最大BML评分≤ 1）或“中度/重度”。使用1：1倾向评分（PS）匹配OA和心血管疾病（CVD）相关潜在混杂变量，选择他汀类药物使用者和非使用者。我们使用调整后的混合效应回归模型评估了他汀类药物使用与BML评分增加和受影响亚区域之间的关联。PS匹配的HN+受试者（63%女性，年龄63.5 ± 8.5岁）无/轻度和中度/重度BML队列分别包括332例（166：166，他汀类药物使用者：非使用者）和380例（190：190）膝关节。在无/极轻微BML的HN+受试者中，他汀类药物的使用与BML评分恶化（比值比，95%置信区间：0.62，0.39-0.98）和受累亚区数量增加（0.54，0.33-0.88）的比值较低相关。在基线中度/重度BML的HN-参与者或HN+参与者中没有这种关联。在有他汀类药物治疗的CVD适应症和全身OA表型（HN+）的患者中，他汀类药物使用可能仅在无/极轻微基线BML的受试者亚组中对OA相关的软骨下骨损伤具有保护作用。
To determine the association between statin therapy and knee MRI-detected subchondral bone marrow lesion (BML) longitudinal worsening in patients with Heberden’s nodes (HNs) as the hallmark of generalized osteoarthritis (OA) phenotype. All participants gave informed consent, and IRB approved HIPAA-compliant protocol. We assessed the worsening in BML volume and number of affected subregions in the Osteoarthritis Initiative (OAI) participants with HNs at baseline clinical examination (HN+), using the semi-quantitative MRI Osteoarthritis Knee Scores at baseline and 24 months. Participants were classified according to baseline BML involvement as “no/minimal” (≤2/14 knee subregions affected and maximum BML score ≤ 1) or “moderate/severe.” Statin users and non-users were selected using 1:1 propensity-score (PS) matching for OA and cardiovascular disease (CVD)–related potential confounding variables. We assessed the association between statin use and increasing BML score and affected subregions using adjusted mixed-effect regression models. The PS-matched HN+ participants (63% female, aged 63.5 ± 8.5-year-old) with no/minimal and moderate/severe BML cohorts consisted of 332 (166:166, statin users: non-users) and 380 (190:190) knees, respectively. In the HN+ participants with no/minimal BML, statin use was associated with lower odds of both BML score worsening (odds ratio, 95% confidence interval: 0.62, 0.39–0.98) and increased number of affected subregions (0.54, 0.33–0.88). There was no such association in HN− participants or those HN+ participants with baseline moderate/severe BML. In patients with CVD indications for statin therapy and generalized OA phenotype (HN+), statin use may be protective against the OA-related subchondral bone damage only in the subgroup of participants with no/minimal baseline BML.
登录
查看更多内容
DOI：
10.1002/art.39731
发表时间：
2016-10
期刊：
Arthritis & rheumatology (Hoboken, N.J.)
影响因子：
--
作者：
Collins JE;Losina E;Nevitt MC;Roemer FW;Guermazi A;Lynch JA;Katz JN;Kent Kwoh C;Kraus VB;Hunter DJ
通讯作者：
Hunter DJ
影响因子：
4.9
作者：
Dore, Dawn;Quinn, Stephen;Jones, Graeme
通讯作者：
Jones, Graeme
影响因子：
19.7
作者：
Haj-Mirzaian, Arya;Mohajer, Bahram;Demehri, Shadpour
通讯作者：
Demehri, Shadpour
影响因子：
4
作者：
Corti, MC;Rigon, C
通讯作者：
Rigon, C
影响因子：
27.4
作者：
Clockaerts, S.;Van Osch, G. J. V. M.;Bierma-Zeinstra, S. M.
通讯作者：
Bierma-Zeinstra, S. M.